End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.035 CAD | -12.50% | -12.50% | +40.00% |
06-05 | NAVCO Pharmaceuticals Inc. Readies Launch of Antimicrobial Line | CI |
05-31 | NAVCO Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024 | CI |
Valuation
Fiscal Period: September | 2023 |
---|---|
Capitalization 1 | 1.211 |
Enterprise Value (EV) 1 | 1.58 |
P/E ratio | -0.42 x |
Yield | - |
Capitalization / Revenue | - |
EV / Revenue | - |
EV / EBITDA | -1.12 x |
EV / FCF | -1,599,675 x |
FCF Yield | -0% |
Price to Book | 13.8 x |
Nbr of stocks (in thousands) | 40,350 |
Reference price 2 | 0.0300 |
Announcement Date | 1/29/24 |
Income Statement Evolution (Annual data)
Fiscal Period: September | 2021 | 2022 | 2023 |
---|---|---|---|
Net sales 1 | 0.0155 | 0.0587 | - |
EBITDA 1 | -0.4949 | -0.4206 | -1.411 |
EBIT 1 | -0.5138 | -0.4502 | -1.441 |
Operating Margin | -3,309.64% | -766.48% | - |
Earnings before Tax (EBT) 1 | -0.5263 | -0.4651 | -2.147 |
Net income 1 | -0.5263 | -0.4651 | -2.147 |
Net margin | -3,389.75% | -791.92% | - |
EPS 2 | -0.0363 | -0.0321 | -0.0711 |
Free Cash Flow | - | -0.1475 | -0.9879 |
FCF margin | - | -251.16% | - |
FCF Conversion (EBITDA) | - | - | - |
FCF Conversion (Net income) | - | - | - |
Dividend per Share | - | - | - |
Announcement Date | 2/6/23 | 2/6/23 | 1/29/24 |
Balance Sheet Analysis
Fiscal Period: September | 2021 | 2022 | 2023 |
---|---|---|---|
Net Debt 1 | 0.57 | 0.9 | 0.37 |
Net Cash position 1 | - | - | - |
Leverage (Debt/EBITDA) | -1.161 x | -2.131 x | -0.262 x |
Free Cash Flow | - | -0.15 | -0.99 |
ROE (net income / shareholders' equity) | - | 83.7% | 613% |
ROA (Net income/ Total Assets) | - | -83.3% | -143% |
Assets 1 | - | 0.5587 | 1.498 |
Book Value Per Share 2 | -0.0200 | -0.0500 | 0 |
Cash Flow per Share 2 | 0 | 0 | 0.0100 |
Capex 1 | 0.07 | - | - |
Capex / Sales | 474.27% | - | - |
Announcement Date | 2/6/23 | 2/6/23 | 1/29/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+12.74% | 387B | |
+13.92% | 138B | |
+21.75% | 78.67B | |
-4.36% | 70.25B | |
-27.28% | 38.17B | |
-14.96% | 35.06B | |
+0.41% | 32.94B | |
+9.36% | 18.28B | |
+21.45% | 16.7B |
- Stock Market
- Equities
- NAV Stock
- NAV Stock
- Financials Navco Pharmaceuticals Inc.